Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)
Close on Nov 18, 2026Market cap $103.35MP/E –Yield –
Cellectis r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $93.52M, up 3.3% from the year before. Over ten years it grew 4.9% a year on average. The highest annual figure on record is $117.84M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.52M | +3.3% |
| FY2024 | Dec 31, 2024 | $90.54M | +3.3% |
| FY2023 | Dec 31, 2023 | $87.65M | -10.1% |
| FY2022 | Dec 31, 2022 | $97.50M | -17.3% |
| FY2021 | Dec 31, 2021 | $117.84M | +52.9% |
| FY2020 | Dec 31, 2020 | $77.05M | -16.3% |
| FY2019 | Dec 31, 2019 | $92.04M | +20.2% |
| FY2018 | Dec 31, 2018 | $76.57M | -3.4% |
| FY2017 | Dec 31, 2017 | $79.23M | +1.0% |
| FY2016 | Dec 31, 2016 | $78.46M | +34.9% |
| FY2015 | Dec 31, 2015 | $58.15M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.98M | -2.6% |
| Q2 FY2025 | Jun 30, 2025 | $23.08M | -25.9% |
| Q2 FY2024 | Jun 30, 2024 | $23.52M | +2.9% |
| Q2 FY2023 | Jun 30, 2023 | $22.20M | -12.7% |
| Q2 FY2022 | Jun 30, 2022 | $25.63M | – |
| Q2 FY2021 | Jun 30, 2021 | $31.15M | – |
| Q2 FY2020 | Jun 30, 2020 | $22.86M | – |
| Q2 FY2019 | Jun 30, 2019 | $25.42M | – |
See a number that looks wrong?